Unveiling #CANMAb™ with Shukrit Chimote, Arun Chandavarkar & Abhijit Barve pic.twitter.com/enfb5qbHDx
— Kiran Mazumdar Shaw (@kiranshaw) January 18, 2014
Note: Biocon has received marketing authorization from the Drugs Controller General (India) (DCGI) for its biosimilar Trastuzumab being developed jointly with Mylan, for the treatment of Her 2+ metastatic breast cancer. The regulatory approval for biosimilar Trastuzumab in India is an important milestone for Biocon as it is the world’s first biosimilar version of Herceptin to be brought to the market. The biosimilar Trastuzumab will be marketed in India under the brand name of CANMAb by Biocon and is expected to be available to Indian patients in Q4 FY14.